GSK punts a failed cardio drug to a biotech startup — which has a new development strategy in mind

More than 3 years after losmapimod proved to be a turkey in a late-stage cardio study at GlaxoSmithKline, the drug has been dusted off and handed over to a startup, which has some new plans in mind for this therapy.